Venadaparib (IDX-1197)
Gastric Cancer
Key Facts
About Idience
Idience is a private, clinical-stage biotech headquartered in San Diego, USA, but founded and wholly owned by Korea's Ildong Holdings. Its lead asset is venadaparib (IDX-1197), a potent PARP inhibitor with FDA Fast Track designation, currently in Phase 1b/2a trials for gastric cancer and other solid tumors. The company operates with a lean, experienced leadership team and a pipeline centered on targeted small molecule therapies, positioning it in the competitive but high-value oncology precision medicine space.
View full company profileAbout Idience
Idience is a private, clinical-stage biotech headquartered in San Diego, USA, but founded and wholly owned by Korea's Ildong Holdings. Its lead asset is venadaparib (IDX-1197), a potent PARP inhibitor with FDA Fast Track designation, currently in Phase 1b/2a trials for gastric cancer and other solid tumors. The company operates with a lean, experienced leadership team and a pipeline centered on targeted small molecule therapies, positioning it in the competitive but high-value oncology precision medicine space.
View full company profileAbout Idience
Idience is a private, clinical-stage biotech headquartered in San Diego, USA, but founded and wholly owned by Korea's Ildong Holdings. Its lead asset is venadaparib (IDX-1197), a potent PARP inhibitor with FDA Fast Track designation, currently in Phase 1b/2a trials for gastric cancer and other solid tumors. The company operates with a lean, experienced leadership team and a pipeline centered on targeted small molecule therapies, positioning it in the competitive but high-value oncology precision medicine space.
View full company profileAbout Idience
Idience is a private, clinical-stage biotech headquartered in San Diego, USA, but founded and wholly owned by Korea's Ildong Holdings. Its lead asset is venadaparib (IDX-1197), a potent PARP inhibitor with FDA Fast Track designation, currently in Phase 1b/2a trials for gastric cancer and other solid tumors. The company operates with a lean, experienced leadership team and a pipeline centered on targeted small molecule therapies, positioning it in the competitive but high-value oncology precision medicine space.
View full company profileTherapeutic Areas
Other Gastric Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| inPROBE for HER2 | SDS Optic | Preclinical/Clinical Data Review |
| VNX-203 | Vironexis Biotherapeutics | Preclinical |
| Gastric PD-L1 | Mindpeak | Commercial |
| Gastric Cancer Biomarkers | Paradise Genomics | Discovery |
| TTFields | Novocure | Pilot |